Immunic (IMUX) EPS (Basic) (2013 - 2026)

Immunic (IMUX) posted EPS (Basic) of -$1.19 for Q1 2026, up 87.06% sequentially from -$9.19 in Q4 2025, and up 54.83% YoY from -$0.77 in Q1 2025.

Analysis

Immunic (IMUX) EPS (Basic) (2013 - 2026) Analysis & Trends

Immunic has reported EPS (Basic) for 14 years, with the latest figure at -$1.19 in Q1 2026.

Quarterly EPS (Basic) rose 54.83% year-over-year to -$1.19 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.71 (up 22.98% YoY) and the FY2025 annual result came in at -$14.26, up 32.52% from the prior year.
EPS (Basic) improved to -$1.19 in Q1 2026 per IMUX's latest filing, from -$9.19 in the prior quarter.
Over five years, EPS (Basic) peaked at -$1.19 in Q1 2026 and troughed at -$40.76 in Q4 2022.
A 5-year average of -$7.83 and a median of -$5.14 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2024: EPS (Basic) slumped 343.93% in 2022, then jumped 90.84% in 2024.
Over 5 years, EPS (Basic) stood at -$40.76 in 2022, then jumped by 32.52% to -$27.5 in 2023, then surged by 90.84% to -$2.52 in 2024, then plunged by 264.55% to -$9.19 in 2025, then surged by 87.06% to -$1.19 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$1.19, -$9.19, and -$1.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	12.62
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	7.70
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	-3.06
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	0.18
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	-0.06
10	Immunic	536.52 Mn	536.52 Mn	-	-0.80

Historic Data

Download Data